"Dermatomyositis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)
Descriptor ID |
D003882
|
MeSH Number(s) |
C05.651.594.819.500 C10.668.491.562.575.500 C17.300.250 C17.800.185
|
Concept/Terms |
Dermatomyositis- Dermatomyositis
- Dermatomyositides
- Juvenile Myositis
- Juvenile Myositides
- Myositides, Juvenile
- Myositis, Juvenile
- Dermatopolymyositis
- Dermatopolymyositides
- Polymyositis-Dermatomyositis
- Polymyositis Dermatomyositis
- Polymyositis-Dermatomyositides
- Juvenile Dermatomyositis
- Dermatomyositides, Juvenile
- Dermatomyositis, Juvenile
- Juvenile Dermatomyositides
Dermatomyositis, Adult Type- Dermatomyositis, Adult Type
- Adult Type Dermatomyositides
- Adult Type Dermatomyositis
- Dermatomyositides, Adult Type
Dermatomyositis, Childhood Type- Dermatomyositis, Childhood Type
- Childhood Type Dermatomyositides
- Childhood Type Dermatomyositis
- Dermatomyositides, Childhood Type
|
Below are MeSH descriptors whose meaning is more general than "Dermatomyositis".
Below are MeSH descriptors whose meaning is more specific than "Dermatomyositis".
This graph shows the total number of publications written about "Dermatomyositis" by people in this website by year, and whether "Dermatomyositis" was a major or minor topic of these publications.
View timeline visualization
Year | Major Topic | Minor Topic | Total |
---|
2000 | 1 | 0 | 1 |
2002 | 1 | 0 | 1 |
2004 | 1 | 1 | 2 |
2005 | 0 | 1 | 1 |
2006 | 1 | 1 | 2 |
2007 | 2 | 0 | 2 |
2008 | 1 | 0 | 1 |
2009 | 3 | 2 | 5 |
2010 | 2 | 0 | 2 |
2011 | 4 | 2 | 6 |
2012 | 1 | 1 | 2 |
2013 | 1 | 1 | 2 |
2014 | 4 | 2 | 6 |
2015 | 2 | 2 | 4 |
2016 | 7 | 2 | 9 |
2017 | 7 | 0 | 7 |
2018 | 8 | 1 | 9 |
2019 | 5 | 2 | 7 |
2020 | 9 | 1 | 10 |
2021 | 11 | 0 | 11 |
2022 | 7 | 0 | 7 |
2023 | 8 | 0 | 8 |
2024 | 6 | 2 | 8 |
Below are the most recent publications written about "Dermatomyositis" by people in Profiles.
-
The Dermatomyositis Disease Symptom Questionnaire (DM-DSQ): A Measure to Assess the Patient Experience of Dermatomyositis Symptoms. J Rheumatol. 2024 Dec 01; 51(12):1198-1207.
-
Childhood Arthritis and Rheumatology Research Alliance Biologic Disease-Modifying Antirheumatic Drug Consensus Treatment Plans for Refractory Moderately Severe Juvenile Dermatomyositis. Arthritis Care Res (Hoboken). 2024 Nov; 76(11):1532-1539.
-
Increased vascular deposition of oxidized LDL in untreated juvenile dermatomyositis. Pediatr Rheumatol Online J. 2024 Aug 08; 22(1):73.
-
Coordinated immune dysregulation in juvenile dermatomyositis revealed by single-cell genomics. JCI Insight. 2024 May 14; 9(12).
-
MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C). EBioMedicine. 2024 Jun; 104:105136.
-
Unique characteristics of anti-MDA-5 associated dermatomyositis in Southern California with a large Hispanic population. Semin Arthritis Rheum. 2024 Jun; 66:152434.
-
Myositis-Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality. Arthritis Rheumatol. 2024 Jun; 76(6):963-972.
-
Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024 01 17; 26(1):27.
-
Artificial intelligence for nailfold capillaroscopy analyses - a proof of concept application in juvenile dermatomyositis. Pediatr Res. 2024 Mar; 95(4):981-987.
-
The Type I Interferon Signature Reflects Multiple Phenotypic and Activity Measures in Dermatomyositis. Arthritis Rheumatol. 2023 10; 75(10):1842-1849.